{"id":"lhrha","safety":{"commonSideEffects":[{"rate":"50–80","effect":"Hot flashes"},{"rate":"40–60","effect":"Decreased libido"},{"rate":"30–50","effect":"Erectile dysfunction"},{"rate":"5–15","effect":"Injection site reactions"},{"rate":"10–20","effect":"Headache"},{"rate":"10–20","effect":"Fatigue"},{"rate":"5–10","effect":"Gynecomastia"}]},"_chembl":null,"_dailymed":{"setId":"0a48b7bb-7b50-4516-93c7-f6c29a66ab9e","title":"LHRHA (LEUTENIZING HORMONE-RELEASING HORMONE ANALOGUE) INJECTION, POWDER, FOR SUSPENSION [WESTERN CHEMICAL INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LHRHa drugs bind to LHRH receptors on pituitary gonadotroph cells, initially causing a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), followed by receptor downregulation and sustained suppression of these hormones. This leads to reduced testosterone in males and estrogen in females, making these agents useful in hormone-dependent cancers and certain reproductive conditions.","oneSentence":"LHRHa (Luteinizing Hormone-Releasing Hormone agonist) suppresses gonadal hormone production by desensitizing the pituitary gland to endogenous LHRH signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:48.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer (hormone-sensitive)"},{"name":"Breast cancer (hormone-sensitive)"},{"name":"Endometriosis"},{"name":"Uterine fibroids"}]},"trialDetails":[{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT06348264","phase":"PHASE2","title":"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-10-10","conditions":"Salivary Gland Neoplasm Duct","enrollment":37},{"nctId":"NCT04181203","phase":"PHASE3","title":"Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-01-09","conditions":"Prostate Cancer","enrollment":490},{"nctId":"NCT02446444","phase":"PHASE3","title":"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2014-03","conditions":"Prostatic Neoplasms","enrollment":802},{"nctId":"NCT06840847","phase":"NA","title":"Sexual Coercion in Breast Cancer Patients Treated With Luteinizing Hormone-Releasing Hormone Agonists (LHRHa )","status":"COMPLETED","sponsor":"Canan Kas","startDate":"2024-01-01","conditions":"Cancer","enrollment":79},{"nctId":"NCT02446405","phase":"PHASE3","title":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2014-03","conditions":"Prostatic Neoplasms","enrollment":1125},{"nctId":"NCT04812366","phase":"PHASE2","title":"Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-09-21","conditions":"Prostate Cancer","enrollment":315},{"nctId":"NCT06611514","phase":"PHASE3","title":"Effect of Intravaginal Prasterone on Symptoms of Genitourinary Syndrome of Menopause (GSM) in Women in Menopause With Previous Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"European Institute of Oncology","startDate":"2024-12-01","conditions":"Women With Breast Cancer","enrollment":95},{"nctId":"NCT06575257","phase":"PHASE2","title":"Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2024-05-01","conditions":"Prostate Cancer","enrollment":80},{"nctId":"NCT03141671","phase":"PHASE2","title":"Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-11-24","conditions":"Prostate Cancer","enrollment":345},{"nctId":"NCT02061345","phase":"","title":"PET Imaging in MCI Following ADT for PCa","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2014-04","conditions":"Prostate Cancer, Mild Cognitive Impairment","enrollment":11},{"nctId":"NCT04136353","phase":"PHASE3","title":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sydney","startDate":"2020-03-31","conditions":"Prostate Cancer","enrollment":1100},{"nctId":"NCT05760222","phase":"NA","title":"Acupuncture Treatment of Vasomotor Symptoms in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-11-25","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT04869371","phase":"PHASE2","title":"Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"Hongqian Guo","startDate":"2018-12-12","conditions":"Neoadjuvant Therapy \\ High Risk Prostate Cancer \\ Docetaxel","enrollment":75},{"nctId":"NCT04356430","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2019-04-01","conditions":"Prostate Cancer","enrollment":75},{"nctId":"NCT04599686","phase":"NA","title":"Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2022-09-11","conditions":"Treatment","enrollment":100},{"nctId":"NCT03279250","phase":"PHASE2","title":"Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":86},{"nctId":"NCT04736108","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2021-05","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT01691976","phase":"NA","title":"Mild Cognitive Impairment in Men Following Androgen Deprivation","status":"WITHDRAWN","sponsor":"Imperial College London","startDate":"2012-10","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT03488810","phase":"PHASE3","title":"Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2020-03-10","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT01790126","phase":"PHASE2","title":"The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-03-04","conditions":"Prostate Cancer","enrollment":90},{"nctId":"NCT01946165","phase":"PHASE2","title":"Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-31","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT01088529","phase":"PHASE2","title":"Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer","status":"COMPLETED","sponsor":"Cougar Biotechnology, Inc.","startDate":"2009-12","conditions":"Prostate Cancer","enrollment":66},{"nctId":"NCT00001190","phase":"PHASE2","title":"Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1983-11","conditions":"Dwarfism, Growth Disorder","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":432,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lupron®","leuprolide","Zoladex®","goserelin"],"phase":"marketed","status":"active","brandName":"LHRHa","genericName":"LHRHa","companyName":"Imperial College London","companyId":"imperial-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LHRHa (Luteinizing Hormone-Releasing Hormone agonist) suppresses gonadal hormone production by desensitizing the pituitary gland to endogenous LHRH signaling. Used for Prostate cancer (hormone-sensitive), Breast cancer (hormone-sensitive), Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}